Results 111 to 120 of about 21,035 (244)

Orolingual Tremor on Smiling [PDF]

Annals of Child Neurology, 2020
Sun Ah Choi, Jeesuk Yu, Hee Hwang, Hunmin Kim   +3 more
doaj   +1 more source

Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency

Epilepsia, EarlyView.
Abstract Objective GRIN‐related disorders due to pathogenic variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders
Maike Karnstedt, Riley E. Perszyk, Scott J. Myers, Ellington McDaniels, Marta Somorai, Ingo Borggraefe, Danielle C. M. Veenma, An‐Sofie Schoonjans, Pasquale Striano, Tadeu A. Fantaneanu, Steffen Syrbe, Kristen Park, Wenjuan Chen, Hongjie Yuan, Stephen F. Traynelis, Timothy A. Benke, Johannes R. Lemke, Ilona Krey   +17 more
wiley   +1 more source

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs

Epilepsia, EarlyView.
Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin, Alexis Arzimanoglou, Jacqueline French, Kelly G. Knupp, Lieven Lagae, Eugen Trinka, Dennis Dlugos, Emilio Perucca   +7 more
wiley   +1 more source

Smiling across borders: Host culture members' reactions to happiness expressed by immigrants. [PDF]

Br J Soc Psychol
Bobowik M, Pizarro JJ, Slawuta P, Basabe N.   +3 more
europepmc   +1 more source

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source

Influence of Hyaluronic Acid Lip Filler Augmentation on Smile Design Parameters in Young Female Population: An Observational Study. [PDF]

Int J Dent
Biadsee A, Biadsee A, Milhem H, Ormianer M, Ormianer Z.   +4 more
europepmc   +1 more source

Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency

Epilepsia, EarlyView.
Abstract Objective Inclusion and exclusion criteria of clinical trials for seizures aim to select representative participants with a high enough seizure frequency to evaluate the efficacy of treatment in a relatively short double‐blind period. To inform the selection of seizure frequency‐based inclusion criteria, we evaluated the association between ...
Wesley T. Kerr, Advith S. Reddy, Neo Kok, Katherine N. McFarlane, Lavanya Biju, Jacqueline A. French   +5 more
wiley   +1 more source

Real world testing and cost‐effectiveness analysis of subcutaneous EEG (REAL‐ASE): Protocol for a prospective multicentre interventional trial

Epilepsia Open, EarlyView.
Abstract Objective Epilepsy is a common condition associated with significant morbidity, mortality, and costs. Poor documentation of seizures is a major challenge in epilepsy care. Objective seizure counting with mobile devices may mitigate this challenge and improve patient management.
Matthew McWilliam, Pedro F. Viana, Eren Dursun, Joe Davies, Joel S. Winston, Jessica Agren, Harutomo Hasegawa, Jonas Duun‐Henriksen, Mark P. Richardson   +8 more
wiley   +1 more source

Cultural adaptation and validation of the mandarin version of the scale of oral health outcomes for 5-year-old children. [PDF]

Front Oral Health
Yu D, Huang D, Ai J, Ma X, Hao Y, Pan Q, Gao SS.   +6 more
europepmc   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source